Revolutionizing Cancer Treatment: Unleashing the Power of Combining Oncolytic Viruses with CAR-T Cells
Authors:
- 1 November 2024
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Anti-Cancer Agents in Medicinal Chemistry
- Vol. 24 (19) , 1407-1418
Abstract
: Oncolytic Viruses (OVs) have emerged as a promising treatment option for cancer thanks to their significant research potential and encouraging results. These viruses exert a profound impact on the tumor microenvironment, making them effective against various types of cancer. In contrast, the efficacy of Chimeric antigen receptor (CAR)-T cell therapy in treating solid tumors is relatively low. The combination of OVs and CAR-T cell therapy, however, is a promising area of research. OVs play a crucial role in enhancing the tumor-suppressive microenvironment, which in turn enables CAR-T cells to function efficiently in the context of solid malignancies. This review aims to provide a comprehensive analysis of the benefits and drawbacks of OV therapy and CAR-T cell therapy, with a focus on the potential of combining these two treatment approaches.Keywords
This publication has 111 references indexed in Scilit:
- A Dual‐Responsive STAT3 Inhibitor Nanoprodrug Combined with Oncolytic Virus Elicits Synergistic Antitumor Immune Responses by Igniting PyroptosisAdvanced Materials, 2023
- Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapyCancer Immunology, Immunotherapy, 2021
- The limiting factors of oncolytic virus immunotherapy and the approaches to overcome themApplied Microbiology and Biotechnology, 2020
- Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitroCancer Immunology, Immunotherapy, 2020
- Analysis of CAR-Mediated Tonic Signaling2019
- Evaluation of Newcastle disease virus mediated dendritic cell activation and cross‐priming tumor‐specific immune responses ex vivoInternational Journal of Cancer, 2019
- The viral approach to breast cancer immunotherapyJournal of Cellular Physiology, 2018
- Oncolytic Virotherapy by HSV2018
- Oncolytic Virotherapy and the Tumor Microenvironment2017
- Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of MelanomaAmerican Journal of Clinical Dermatology, 2016